Search clinical trials for: Anti-PD-1 alone

Total 5949 results

Pyrotech Therapeutics, Inc.

Recruiting

PTT-936 Alone or in Combination in Patients With Locally Advanced or Metastatic Solid Tumors

Locally Advanced or Metastatic Solid Tumors

United States
CSPC ZhongQi Pharmaceutical Technology Co., Ltd.

Recruiting

Study of Recombinant Human Anti-PD-1 Monoclonal Antibody in Patients With Advanced Tumours

Lymphoma | Cervical Cancer | Malignant Mesothelioma | Advanced Solid Tumours | Non-Small-Cell Lung Cancer

China
Agenus Inc.

Recruiting

Fc-Engineered Anti-CTLA-4 Monoclonal Antibody in Advanced Cancer

Melanoma | Ovarian Cancer | Prostate Cancer | Non-small-cell Lung Cancer | Endometrial Cancer | Advanced Cancer | Angiosarcoma | Fibrolamellar Carcinoma | Colorectal Cancer Without Liver Metastases

United States
Themis Bioscience GmbH
Assign Data Management and Biostatistics GmbH; Optimapharm

Withdrawn

A Safety Study of TMV-018 in Patients With Tumors of the Gastrointestinal Tract

Gastrointestinal Cancer

Germany
Northwestern University
National Cancer Institute (NCI)

Recruiting

Vudalimab for the Treatment of Locally Advanced or Metastatic Anaplastic Thyroid Cancer or Hurthle Cell Thyroid Cancer

Locally Advanced Thyroid Gland Anaplastic Carcinoma | Metastatic Thyroid Gland Anaplastic Carcinoma | Metastatic Thyroid Gland Oncocytic Carcinoma

United States
Shandong Provincial Hospital

Unknown

Study of PD-1 Monoclonal Antibody in Combination With Chemotherapy in Patients With RR NHL

Relapsed/Refractory Non-Hodgkin's Lymphoma

China
Shanghai Cell Therapy Research Institute

Unknown

CTLA-4 and PD-1 Antibodies Expressing EGFR-CAR-T Cells for EGFR Positive Advanced Solid Tumor

Advanced Solid Tumor

China
Fudan University
Shanxi Province Cancer Hospital; Inner Mongolia Cancer Hospital Affiliated...

Recruiting

A Retrospective and Prospective Real-world Study of Molecular Typing in the Treatment of Advanced Thyroid Cancer

Advanced Thyroid Cancer Patients Who Received Target Therapy

China
Adanate, Inc

Recruiting

A Phase 1 Study of ADA-011 for Subjects With Advanced Solid Tumors

Solid Tumor, Adult

United States
Symphogen A/S

Completed

Sym021 Monotherapy, in Combination With Sym022 or Sym023, and in Combination With Both Sym022 and Sym023 in Patients With Advanced Solid Tumor Malignancies or Lymphomas

Lymphoma | Solid Tumor | Metastatic Cancer

Canada, United States
Cancer Institute and Hospital, Chinese Academy...

Recruiting

Postoperative Management for HNSCC Based on Pathological Response of Induction Chemotherapy and Immunotherapy (HN)

Head and Neck Cancer

China
Shanghai Cell Therapy Research Institute

Unknown

CTLA-4 and PD-1 Antibodies Expressing MUC1-CAR-T Cells for MUC1 Positive Advanced Solid Tumor

Advanced Solid Tumor

China
Guangzhou Gloria Biosciences Co., Ltd.

Recruiting

Study of GLS-010 Injection in Patients With Recurrent or Metastatic Cervical Cancer (CC)

Cervical Cancer

China
Guangzhou Gloria Biosciences Co., Ltd.

Completed

Study of Recombinant Human Anti-PD-1 Monoclonal Antibody for Patients With Advanced Solid Tumors

Advanced Solid Tumors

China
Fudan University

Withdrawn

GP Chemotherapy in Combination With Tislelizumab and Ociperlimab as First-line Treatment in Advanced BTC

Intrahepatic Cholangiocarcinoma

China
Novita Pharmaceuticals, Inc.

Recruiting

NP-G2-044 as Monotherapy and Combination Therapy in Patients With Advanced or Metastatic Solid Tumor Malignancies

Advanced or Metastatic Solid Tumor Malignancies

United States
Chongqing University Cancer Hospital

Recruiting

The Efficacy of Camrelizumab Plus Stereotactic Body Radiotherapy in R/M NPC

Nasopharyngeal Carcinoma

China
Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University
Guangzhou Anjie Biomedical Technology Co., Ltd.

Completed

PD-1 Knockout Anti-MUC1 CAR-T Cells in the Treatment of Advanced Breast Cancer

Advanced Breast Cancer | Breast Neoplasm Malignant Female

China
Guangzhou Gloria Biosciences Co., Ltd.

Unknown

Study of GLS-010 Injection in the Treatment of Classical Hodgkin's Lymphoma

Classical Hodgkin's Lymphoma

China
Hospices Civils de Lyon

Completed

Anti-PD-1 and Chemotherapy for R/R Hodgkin Lymphoma

Hodgkin Lymphoma

France
Dalian University

Unknown

Treatment of Non-small Cell Lung Cancer With Cytokine-induced Killer (CIK) Cells Blocked by PD-1 Antibody

Non-small Cell Lung Cancer
Hunan Cancer Hospital

Recruiting

Anti-PD-1 Antibody Combined With Peg-Asparaginase and Chidamide for the Early Stage of NK/T Cell Lymphoma

Chemotherapy Effect | NK/T-cell Lymphoma of Nasal Cavity | Immune Checkpoint Inhibitor | Epigenetic Disorder

China
Pfizer

Completed

A Pilot Study To Investigate The Effect Of Concurrent Antacid Administration On The Bioavailability Of Six Experimental Formulations Of Palbociclib

Healthy

United States
Mahmoud Ramadan mohamed Elkazzaz

Not yet recruiting

CRISPR/Cas9-modified Human T Cell ( PD-1and ACE2 Knockout Engineered T Cells ) for Inducing Long-term Immunity in COVID-19 Patients

COVID-19 Respiratory Infection
Second Affiliated Hospital, School of Medicine,...
Westlake Therapeutics

Recruiting

WTX212A Monotherapy and in Combination With PD -1/PD-L1 Monoclonal Antibody

Advanced Lung Cancer

China
Genor Biopharma Co., Ltd.

Recruiting

Clinical Trial in Chinese Patients of Elapsed/Metastatic/Unresectable Alveolar Soft Part Sarcoma(GB226)

Alveolar Soft Part Sarcoma

China
Shanghai Zhongshan Hospital

Not yet recruiting

Gut Microbiota Reconstruction for NSCLC Immunotherapy

Non-Small Cell Lung Cancer

China
Shanghai Henlius Biotech

Recruiting

A Clinical Study of HLX10 Combined With Chemotherapy Versus Placebo Combined With Chemotherapy for Neoadjuvant/Adjuvant Treatment of Gastric Cancer

Gastric Cancer

China
Guangxi Medical University

Unknown

RT+ Anti-PD-1 for Patients With Advanced HCC (RT+PD-1-HCC)

Hepatocellular Carcinoma
Genor Biopharma Co., Ltd.

Recruiting

Clinical Trial in Chinese Patients of Relapsed and Refractory Peripheral T Cell Lymphoma (GB226)

Peripheral T Cell Lymphoma

China
Vestre Viken Hospital Trust
Oslo University Hospital; University Hospital of North Norway; Helse Stavanger... and other collaborators

Recruiting

Efficacy and Safety of Anti-PD-1/PD-L1 Treatment +/- UV1 Vaccination in Patients With Non-small Cell Lung Cancer (LUNGVAC)

Oncology | NSCLC Stage IV | NSCLC, Stage III

Norway
Beijing Friendship Hospital

Recruiting

DEP Combine With PD-1 Antibody as an Treatment for EBV-HLH

Hemophagocytic Lymphohistiocytosis

China
SecuraBio

Terminated

A Study of Duvelisib in Combination With Pembrolizumab in Head and Neck Cancer

Head and Neck Squamous Cell Carcinoma

United States
Jounce Therapeutics, Inc.

Completed

Study of JTX-8064, as Monotherapy and in Combination With a PD-1 Inhibitor, in Adult Subjects With Advanced Refractory Solid Tumors

Cancer

United States
Peking University

Recruiting

HAIC Combine With Lenvatinib and PD-1 Inhibitors for Advanced HCC With PVTT

Hepatocellular Carcinoma | Portal Vein Thrombosis

China
University of Colorado, Denver
US Endoscopy

Recruiting

Evaluation of Pancreatic Cystic Lesions Via EUS-guided Fine Needle Aspiration With and Without Micro Forceps Biopsies

Pancreatic Cyst

United States
Beijing YouAn Hospital
Beijing Gene Key Life Technology Co., Ltd.

Recruiting

Adoptive Autologous iNKT Cells for the Treatment of Progressed Hepatocellular Carcinoma Continuing on PD-1 Inhibitor Therapy

Hepatocellular Carcinoma

China
Peking University First Hospital
YiZhou International Cancer Hospital

Unknown

Combination of Hypofractionated Proton Therapy With Immunotherapy (I-HypoPT)

Immunotherapy | Proton Therapy
Second Affiliated Hospital, School of Medicine,...

Recruiting

Single-center, Prospective Cohort Study of PD-1 Inhibitors on Clinical Outcomes of Carotid Plaques in Tumor Patients

Carotid Artery Plaque | Pd-1 Inhibitors

China
Dong Wang

Not yet recruiting

TC Plus PD-1 Inhibitors Combined With Anlotinib for Advanced Advanced Esophageal Cancer (TC)

ESCC

China
Wu Jun

Recruiting

Efficacy and Safety of Fruquintinib in Combination With PD-1 Inhibitors as First-line Maintenance Therapy for Advanced HER-2 Negative Gastric Cancer: a Single-arm, Prospective, Exploratory Clinical Study

Gastric Cancer

China
Second Affiliated Hospital of Soochow University
SciClone Pharmaceuticals

Recruiting

Thymalfasin-based PRaG Mode for Advanced Refractory Solid Tumors

Advanced Solid Tumor | Refractory Tumor

China
Shanghai Pulmonary Hospital, Shanghai, China
The University of Hong Kong

Not yet recruiting

Impact of Inactivated Trivalent Influenza Vaccine on NSCLC Patients Receiving PD-1 / PD-L1 Inhibitors

Non Small Cell Lung Cancer | Influenza Vaccine

China
Sun Yat-sen University

Not yet recruiting

A Prospective Study: Sintilimab and R-CHOP in PMBCL Treatment

Primary Mediastinal Large B Cell Lymphoma
RenJi Hospital

Completed

Neoadjuvant PD-1 Monoclonal Antibody in Cisplatin-ineligible High Risk Upper Tract Urothelial Carcinoma

Neoadjuvant Immunotherapy of Cisplatin-ineligible High Risk Upper Urinary Tract Urothelial Carcinoma

China
Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University

Recruiting

Correlation Between Pre-transplant ICI Exposure and Post-transplant Graft Rejection

Hepatocellular Carcinoma | Graft Rejection | Immunotherapy | Immune Checkpoint Inhibitor

China
The First Affiliated Hospital with Nanjing Medical...

Recruiting

A Study of Tislelizumab Combined With Radiotherapy as the Second-line Treatment of Advanced Biliary Malignant Tumors

Cholangiocarcinoma

China
Shanghai Zhongshan Hospital

Recruiting

Neoadjuvant Anti-PD-1 Plus Chemotherapy in Locally Advanced Resectable Esophageal Squamous Cell Carcinoma

Esophageal Squamous Cell Carcinoma | Neoadjuvant Chemoimmunotherapy

China
CSPC ZhongQi Pharmaceutical Technology Co., Ltd.

Not yet recruiting

A Study of Duvelisib Combined With SG001 Injection in Patient With Advanced Solid Tumors

Advanced Solid Tumors
University Hospital, Bordeaux

Recruiting

Treatment Pause Versus Treatment Continuation in IMDC Good or Intermediate Risk With Only One Adverse Prognostic Factor in mRCC Patients With an Objective Response at 12 Months of Treatment With PD1/ PDL1 ICIs + VEGFR-Tyrosine Kinase Inhibitors (SPICI)

Metastatic Renal Cell Carcinoma | Good or Only One Adverse Prognostic Factor Intermediate Risk Per IMDC Score

France

Search clinical trials for: Anti-PD-1 alone

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Turkmenistan

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations